Evotec
EVO
1.57
-0.05
-2.80%
Evotec
US · EVO
#3659 by market cap
Listed 2021
1.57
-0.05
-2.80%
Live - 5344 symbols - heartbeat 151s ago
· 2026-10-08 10:03
Pre-market
1.58
-1.86%
After-hours
1.61
0.00%
Overnight
1.58
-1.86%
- Market cap
- 556.18M
- P/E (TTM)i
- -2.52
- P/Bi
- 0.75
- EPSi
- -0.33
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on EVO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.37, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -1.08% YoY
Margins
- Gross margin
- 14.49%
- Operating margin
- -7.08%
- Net margin
- -13.13%
Key ratios & quality
- Enterprise valuei
- 540.86M
- Altman Z-Scorei
- 0.37
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 375.41M | 446.44M | 500.92M | 618.03M | 751.45M | 781.43M | 796.97M | 788.37M |
| Gross profit | 112.02M | 132.89M | 125.74M | 151.54M | 174.07M | 175.05M | 114.88M | 114.22M |
| Selling & admin expenses | 57.01M | 66.43M | 77.21M | 105.45M | 156.19M | 169.61M | 188.20M | 175.97M |
| Research & development | 30.19M | 54.56M | 59.61M | 65.70M | 76.64M | 68.53M | 50.86M | 37.51M |
| Operating profit | 66.43M | 74.63M | 51.80M | 41.68M | 20.85M | -26.63M | -78.92M | -55.82M |
| Pretax profit | 72.00M | 56.68M | 25.84M | 236.98M | -153.96M | -80.59M | -193.98M | -86.77M |
| Tax | -12.06M | 19.36M | 19.56M | 21.47M | 21.70M | 3.32M | 2.10M | 16.75M |
| Net profit | 84.06M | 37.31M | 6.28M | 215.51M | -175.66M | -83.91M | -196.08M | -103.52M |
| Basic EPS | 0 | 0 | 0 | 1 | 0 | 0 | -1 | 0 |
| Diluted EPS | 0.28 | 0.13 | 0.02 | 0.65 | -0.50 | -0.24 | -0.56 | -0.29 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 199.98M | 171.24M | 163.89M | 253.27M | 156.64M | 143.48M |
| Gross profit | 33.24M | 8.59M | -62.00K | 78.46M | -1.57M | -1.58M |
| Selling & admin expenses | 49.54M | 41.61M | 42.31M | 44.35M | 43.79M | 39.29M |
| Research & development | 14.93M | 8.21M | 8.71M | 9.83M | 10.08M | 10.26M |
| Operating profit | -19.82M | -28.60M | -44.61M | 37.21M | -46.42M | -89.32M |
| Pretax profit | -29.85M | -43.42M | -42.96M | 29.46M | -122.18M | -48.12M |
| Tax | 1.73M | 59.00K | 127.00K | 14.84M | -244.00K | -1.47M |
| Net profit | -31.58M | -43.48M | -43.09M | 14.62M | -121.94M | -46.65M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.09 | -0.12 | -0.12 | 0.05 | -0.35 | -0.13 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 249.77M | 469.53M | 658.84M | 1.10B | 1.07B | 903.16M | 681.96M | 762.95M |
| Cash & ST investments | 149.88M | 321.66M | 492.63M | 858.50M | 707.31M | 604.11M | 367.68M | 463.02M |
| Inventory | 5.66M | 10.75M | 13.59M | 25.79M | 29.83M | 30.89M | 31.12M | 29.32M |
| Total assets | 771.88M | 1.18B | 1.46B | 2.24B | 2.26B | 2.25B | 1.91B | 1.71B |
| Total current liabilities | 196.28M | 178.96M | 208.46M | 324.52M | 337.71M | 464.57M | 344.59M | 368.07M |
| Short-term debt | 56.92M | 20.73M | 30.01M | 50.61M | 16.38M | 149.10M | 50.80M | 103.68M |
| Long-term debt | 54.68M | 324.89M | 331.02M | 326.34M | 328.30M | 477.11M | 392.74M | 344.01M |
| Total liabilities | 347,003,000.00 | 703,883,000.00 | 737,881,000.00 | 857,476,000.00 | 1,070,063,000.00 | 1,132,560,000.00 | 959,977,000.00 | 900,241,000.00 |
| Total equity | 424.88M | 477.03M | 724.46M | 1.38B | 1.19B | 1.12B | 952.53M | 813.70M |
| Retained earnings | -481.01M | -441.18M | -432.64M | -216.42M | -392.38M | -476.29M | -672.37M | -775.89M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 723.88M | 604.45M | 793.12M | 762.95M | 711.28M | 728.89M |
| Cash & ST investments | 378.71M | 356.40M | 242.80M | 463.02M | 463.78M | 483.62M |
| Inventory | 33.51M | 34.56M | 31.18M | 29.32M | 32.98M | 38.56M |
| Total assets | 1.94B | 1.81B | 1.77B | 1.71B | 1.64B | 1.57B |
| Total current liabilities | 356.92M | 383.19M | 374.47M | 368.07M | 423.37M | 312.46M |
| Short-term debt | 60.92M | 106.86M | 96.87M | 103.68M | 88.62M | 61.54M |
| Long-term debt | -- | -- | -- | 344.01M | 298.85M | 414.32M |
| Total liabilities | 1,032,761,000.00 | 962,472,000.00 | 972,564,000.00 | 900,241,000.00 | 940,192,000.00 | 908,397,000.00 |
| Total equity | 912.14M | 845.79M | 800.14M | 813.70M | 699.62M | 665.58M |
| Retained earnings | -703.95M | -747.42M | -790.51M | -775.89M | -897.82M | -944.47M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 156.24M | 42.22M | 44.72M | 126.60M | 205.81M | 36.44M | 18.22M | -9.18M |
| Depreciation & amortization | 31.29M | 48.81M | 56.06M | 70.40M | 83.20M | 92.98M | 101.62M | 99.48M |
| Free cash flow | 128.37M | 10.31M | -54.35M | 7.66M | 24.46M | -179.56M | -114.02M | -91.80M |
| Dividends paid | -- | -- | -- | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | -- | 0 | 249.97M | 404.32M | 355.00K | 0 | 0 | -1.55M |
| Ending cash balance | 109.06M | 277.03M | 422.58M | 699.33M | 415.16M | 510.91M | 306.39M | 418.52M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -31.81M | 26.56M | -67.56M | 63.63M | -3.92M | -107.19M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -53.65M | 2.70M | -88.96M | 48.11M | -14.70M | -118.20M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 285.38M | 267.83M | 179.27M | 418.52M | 387.91M | 348.36M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 22.30 | 8.45 | 1.04 | 20.52 | -13.70 | -7.27 | -18.92 | -11.72 |
| ROA %i | 11.70 | 3.90 | 0.47 | 11.66 | -7.82 | -3.72 | -9.42 | -5.71 |
| ROIC %i | 16.12 | 5.61 | 1.04 | 14.29 | -9.61 | -4.78 | -12.07 | -7.26 |
| 5-year avg ROE %i | 9.99 | 12.56 | 10.85 | 12.19 | 7.72 | 1.81 | -3.67 | -6.22 |
| EBIT margin %i | 19.87 | 14.34 | 6.84 | 39.84 | -18.74 | -8.81 | -22.87 | -9.17 |
| FCF / sales %i | 34.20 | 2.31 | -- | 0.53 | 2.89 | -- | -- | -- |
| Current ratioi | 1.27 | 2.62 | 3.16 | 3.39 | 3.18 | 1.94 | 1.98 | 2.07 |
| Quick ratioi | 1.18 | 2.49 | 2.95 | 3.19 | 2.91 | 1.78 | 1.70 | 1.84 |
| Debt / assetsi | 14.83 | 39.22 | 33.64 | 22.95 | 22.45 | 27.80 | 23.19 | 26.12 |
| LT debt / equityi | 13.57 | 92.73 | 63.77 | 33.56 | 41.30 | 42.60 | 41.23 | 42.28 |
| Interest coveragei | 28.79 | 8.59 | 4.05 | 26.61 | -10.71 | -5.87 | -15.58 | -5.01 |
| Revenue CAGR (3Y) %i | 43.26 | 39.48 | 23.84 | 18.08 | 18.95 | 15.98 | 8.85 | 1.61 |
| Net income CAGR (3Y) %i | 72.09 | 11.49 | -35.57 | 36.80 | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | 213.79 | -43.51 | -- | -60.93 | 33.36 | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -20.51 | -16.75 | -17.98 | -11.72 | -24.06 | -26.08 |
| ROA %i | -9.97 | -8.17 | -8.45 | -5.71 | -10.82 | -11.65 |
| ROIC %i | -17.95 | -14.66 | -15.68 | -7.26 | -15.95 | -15.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -23.55 | -15.61 | -15.47 | -9.17 | -22.08 | -24.01 |
| FCF / sales %i | -- | 1.60 | -- | -- | -- | -- |
| Current ratioi | 2.03 | 1.58 | 2.12 | 2.07 | 1.68 | 2.33 |
| Quick ratioi | 1.77 | 1.37 | 1.16 | 1.84 | 1.49 | 2.08 |
| Debt / assetsi | 3.13 | 5.91 | 5.46 | 26.12 | 23.63 | 30.23 |
| LT debt / equityi | -- | -- | -- | 42.28 | 42.72 | 62.25 |
| Interest coveragei | -16.23 | -8.26 | -7.75 | -5.01 | -11.25 | -14.85 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Discovery & Preclinical Development (D&PD) is the largest reported line at 76.54% of revenue, across 3 reported segments.
- The next-largest line, Just - Evotec Biologics (JEB), is a distant second at 23.52% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Discovery & Preclinical Development (D&PD)76.54%
Just - Evotec Biologics (JEB)23.52%
Quote time 2026-10-08 10:03:19 · For reference only, not investment advice and not tailored to your situation.